1. Introduction {#s0005}
===============

Phospholipases A~2~ (EC 3.1.1.4), also called PLA~2~, are a group of largely studied enzymes that hydrolyze phospholipids at the *sn*-2 position, releasing lysophospholipids and fatty acids. In snake venoms (as well as in other venomous animals) these proteins present an important hole not only in the digestion process, but can exhibit several pharmacological effects that will lead to or help in the capture of prey [@bib20].

The PLA~2~ are divided into 5 families (cytosolic, secretory, Ca++-independent, PAF acetylhydrolases, and the lysosomal) and 16 major groups. The snake venom PLA~2~ are comprised into the secretory phospholipase A~2~ family (sPLA~2~), characterized by the small size (13--18 kDa), tertiary structure with 5--8 disulfide bridges, the presence of histidine in the active site and requirement of Ca^++^ for catalysis [@bib30], [@bib8]. The secreted PLA~2~ of New World Viperidae are classified into group IIA, with a molecular mass varying between 13 and 15 kDa, seven conserved disulfide bridges and a seven residues C-terminal tail [@bib14], [@bib33].

Different isoforms of PLA~2~ may exhibit one or more different pharmacological effects (which can happen through direct action or because of the product of its catalysis) like myotoxicity, cardiotoxicity, necrosis, anticoagulation, neurotoxicity, cytotoxicity and others [@bib19], [@bib7]. One single species can contain different isoforms of these molecules, which can be, in some cases, acidic. Despite of its activity, the acidic PLA~2~ usually shows weak neurotoxicity, myotoxicity and lethal potency in vivo, but induces other significant pharmacological effects such as inhibition of platelet aggregation, hypotension, inflammatory effects and cytotoxicity.

The different isoforms found in a snake venom perform different roles, like prey immobilization or digestion. The differences in the amino acid sequence and consequent structural differences will respond for such divergences in activities and biochemical properties.

*Porthidium hyoprora* is an endemic species from northwest region of South America, inside Amazon Forest [@bib5]. Such geographical isolation may lead to significant differences in the biochemical composition of snake venom or specific proteins. The evolution process along geographical isolation might origin different variants of a protein, creating a diversity of pharmacological effects, and that would include PLA~2~s with different characteristics [@bib11].

The structure-function relationship in PLA~2~ enzymes is not completely clear for all the effects already reported. It remains an unsolved question why some isoforms can perform specific roles while others, although very similar, cannot. The lack of some properties by some phospholipases A~2~ and the slight differences in their structures are clues to understand how such toxins act [@bib6].

In the present work, a new acidic PLA2, called PhTX-III, was isolated from *Porthidium hyoprora* venom and characterized in its structure, biochemistry and pharmacological properties, in an effort to comprehend more about this class of enzymes.

2. Material and methods {#s0010}
=======================

2.1. PhTX-III obtaining {#s0015}
-----------------------

*Porthidium hyoprora* crude venom (Sigma-Aldrich Chemical Co.; St. Louis, MO, USA) was purified through two chromatographic steps. First, 50 mg of crude venom was dissolved in 1 ml of Ammonium bicarbonate buffer (AMBIC) 1 M, pH 8.0 and then centrifuged at 9000*g* for 5 min. The supernatant was submitted to gel filtration chromatography using Sephadex G75 column (1.5 cm×100 cm), previously equilibrated with AMBIC 50 mM, under a flow rate of 12 ml/h. The PLA~2~ active pool was selected, lyophilized and 5 mg of it was dissolved in 120 μl of 0.1% (v/v) trifluoroacetic acid (solvent A) and 80 μl of AMBIC. The solution was again centrifuged at 9000*g* for 5 min and the supernatant was submitted to a reverse phase chromatography in a C5 Supelco (0.78×30 cm) column previously equilibrated with Solvent A. Samples were eluted with a linear gradient (0--100%, v/v) of acetonitrile 66% (solvent B) at a constant flow rate of 1.0 ml/min over 70 min. The elution profile was monitored at 280 nm, and the collected fractions were lyophilized and conserved at −20 °C ([Fig. 1](#f0005){ref-type="fig"}A). All chemicals and reagents were of analytical or sequencing grade.Fig. 1(A) Elution profile of a reverse phase chromatography of the selected pool from gel filtration (pool II), using Supelco C5 column. In gray, the selected fraction, PhTX-III. (B) Deconvoluted Maldi-TOF mass spectrum of PhTX-III used to determine exact protein mass and attesting homogeneity of sample.

2.2. PLA~2~ activity {#s0020}
--------------------

PLA~2~ activity was measured using the assay described by Cho and Kezdy [@bib4] and Holzer and Mackessy [@bib15]. The standard assay mixture contained 200 μL of buffer (10 mM Tris--HCl, 10 mM CaCl2 and 100 mM NaCl, pH 8.0), 20 μL of substrate 4-nitro-3-(octanoyloxy) benzoic acid (3 mM), 20 μL of water and 20 μL of the testing sample in a final volume of 260 μL. The mixture was incubated for up to 40 min at 37 °C, and absorbance was monitored at every 10 min. The enzyme activity, expressed as the initial velocity of the reaction (*V*~0~), was calculated based on the increase of absorbance after 20 min.

2.3. PhTX-III kinetic parameters {#s0025}
--------------------------------

For evaluation of different conditions in PLA~2~ activity, the above-described assay was performed with only punctual changes in the desired parameter. For temperature evaluation, the assay was performed varying temperature from 25 °C to 45 °C. The pH influence over activity was evaluated using different buffers: Sodium citrate buffer (pHs 4.0--5.0); Tris--HCl buffer (6.0--8.0); glicine buffer (9.0--10.0). The influence of divalent ions in reaction was performed either by substituting the Ca^2+^ by Ba^2+^, Zn^2+^, Mn^2+^ or Mg^2+^, or adding these ions and reducing the amount of calcium from 10 mM to 1 mM. Influence of substrate concentration was measured by varying 4-nitro-3-(octanoyloxy) benzoic acid concentration from 0.05 to 10 mM.

2.4. Molecular mass determination by mass spectrometry {#s0030}
------------------------------------------------------

An aliquot (45 μL) of the PhTX-III was injected into a C18 column (100 μm×100 μm) in a RP-UPLC (nanoAcquity UPLC, Waters). The UPLC was coupled with nanoelectrospray tandem mass spectrometry on a Q-T of Ultima API mass spectrometer (MicroMass/Waters) at a flow rate of 600 nl/min. The gradient was 0--50% acetonitrile in 0.1% formic acid over 45 min. The instrument was operated in MS continuum mode and the data acquisition was from *m*/*z* 100 to 3000 at a scan rate of 1 s and an interscan delay of 0.1 s. The spectra were accumulated over about 300 scans and the multiple charged data produced by the mass spectrometer on the *m*/*z* scale were converted to the mass (molecular weight) scale using maximum-entropy-based software supplied with Masslynx 4.1 software package. The processing parameters were: output mass range 6000--20,000 Da at a "resolution" of 0.1 Da/channel; the simulated isotope pattern model was used with the spectrum blur width parameter set to 0.2 Da and the minimum intensity ratios between successive peaks were 20% (left and right). The deconvoluted spectrum was then smoothed (2×3 channels, Savitzky Golay smooth) and the mass centroid values obtained using 80% of the peak top and a minimum peak width at half height of four channels.

2.5. Tryptic digestion and analysis {#s0035}
-----------------------------------

The protein was reduced with DTT (in a final concentration of 5 mM) for 25 min at 56 °C and alkylated with Iodoacetamide (in a final concentration of 14 mM) for 30 min prior to the addition of trypsin (Promega׳s sequencing grade modifed). After trypsin addition (20 ng/μL in ammonium bicarbonate buffer 0.05 M), the sample was incubated for 16 h at 37 °C. To stop the reaction, formic acid 0.4% was added and the sample centrifuged at 2500 rpm for 10 min. The pellet was discarded and the supernatant dried in a speed vac. The resulting peptides were separated by C18 (100 µm×100 mm) RP-UPLC (nanoAcquity UPLC, Waters) coupled with nanoelectrospray tandem mass spectrometry on a QTof Ultima API mass spectrometer (MicroMass/Waters) at a flow rate of 600 nl/min. Before performing a tandem mass spectrum, an ESI/MS mass spectrum (TOF MS mode) was acquired for each HPLC fraction over the mass range of 100--2000*m*/*z*, in order to select the ion of interest; subsequently, these ions were fragmented in the collision cell (TOF MS/MS mode). Raw data Files from LC--MS/MS runs were processed using Masslynx 4.1 software package (Waters) and analyzed using the MASCOT search engine version 2.3 (Matrix Science Ltd.) against the snakes database, using the following parameters: peptide mass tolerance of ±0.1 Da, fragment mass tolerance of ±0.1 Da, and oxidation as variable modifications in methionine and trypsin as enzyme.

2.6. Miotoxicity evaluation {#s0040}
---------------------------

Swiss male mice (18--20 g; *n*=5) received an intramuscular (i.m.) or an intravenous (i.v.) injection of 20 µg of PhTX-III in phosphate-buffered saline (PBS; 0.12 M NaCl, 0.04 M sodium phosphate, pH 7.2) in a total volume of 50 µl. The i.m. group received the injection in the gastrocnemius muscle and the i.v. group in the tail vein. Control groups received only PBS. Blood was collected from the tail into heparinized capillary tubes after two hours and the plasmatic creatine kinase (CK; EC 2.7.3.2) activity was determined by a kinetic assay Ck-Nac, (creatine kinase, Beacon Diagnostics, Germany). The results were expressed as U/L according to the manufacturer.

2.7. Antibacterial activity {#s0045}
---------------------------

The antibacterial capacity of PhTX-III was tested using agar diffusion test, according to Bauer (1966). Six bacteria strains were used: *Escherichia coli* (*E. coli* ATCC 25922), *Pseudomonas aeruginosa* (*P. aeruginosa* ATCC 27853; *P. aeruginosa* 31NM) and *Staphylococcus aureus* (*S. aureus* ATCC 25923; *S. aureus* BEC9393; *S. aureus* Rib1). Commercially available antibiotics Ofloxacin and Imipinen were used as positive controls. The isolated PLA~2~ was tested in crescent doses until 200 µg/ml.

2.8. Anticoagulant activity {#s0050}
---------------------------

Swiss male mice blood was used in the two different anticoagulant tests. Activated partial thromboplastin time (aPTT) and the prothrombin time (PT) tests. The blood was collected by cardiac puncture in 3.8% citrate-contained tubes in a volume ratio of 9:1. Blood was centrifuged and only plasma used in the tests. The volume of plasma used in the experiments was 45 µl with 5 µl of toxin solution. Control tests used 50 µl of plasma. Both tests used commercially available kits and automatic coagulometer.

2.9. Rat paw edema induction {#s0055}
----------------------------

Swiss male mice (18--20 g; *n*=5) received subplantar injections from 5 to 40 μg of PhTX-III in PBS; in a total volume of 50 µl. Control groups received only the PBS. The paw swelling was measured with an Electronic Caliper Series 1101 (INSIZE LTDA, SP, Brazil) at 0.5, 3, 6, and 24 h after administration. Edema was expressed as the percentual increase in the size of the treated group compared to the control group at each time. Minimal edematogenic dose was defined as the dose necessary to cause an increase of 30% in paw size.

2.10. Cytokines quantification {#s0060}
------------------------------

Swiss male mice (18--20 g; *n*=5) were injected a 10 µg dose of PhTX-III in the tibial muscle. Afterwards, blood samples were collected from the animals at different times using heparinized capillaries to check the plasma cytokines profile over time. Interleukin 1α (IL-1α), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) concentrations were determined using commercially available ELISA kits (BD OptEIA, BD Biosciences) following provided instructions.

2.11. Morphological analysis {#s0065}
----------------------------

Swiss male mice (18--20 g; *n*=5) gastrocnemius muscles were injected 10 μg of PhTX-III dissolved in PBS, in a total volume of 50 μl or only PBS buffer (control). After one hour, the animals were euthanized by cervical dislocation and had the muscles removed and fixed with formaldehyde 10% solution in Millonig׳s buffer (0.13 M sodium phosphate, 0.1 M NaOH, pH 7.4) for twelve hours at 4 °C. After that, the injected muscles were washed in water, ethanol dehydrated, diaphanized with xylene and paraffin-embedded. Longitudinal and transversal sections of 7 µm were stained by hematoxylin--eosin (HE) and Dominici staining and were analyzed under a Carl Zeiss Axio Scope.A1 light microscope. Photographs were obtained using Carl Zeiss AxioCam ICc3.

Modified Dominici staining was performed based on Litt [@bib22]. Sections were stained in a mixture of Acid fucsin and Orange G for 30 min. After a quick rinse in ethanol 60%, they were stained in Toluidine blue 0.75% for 20 s. Solutions were prepared according to Tolosa [@bib35].

3. Results {#s0070}
==========

3.1. Enzyme structure studies {#s0075}
-----------------------------

The mass spectrometry attested the toxin homogeneity after purification and revealed its exact molecular mass as 13,620.9 Da ([Fig. 1](#f0005){ref-type="fig"}B).

The peptides obtained by the tryptic digestion were submitted to MS/MS analysis, and the raw data were processed using Mascot MS/MS Ion Search software. It was possible to obtain 86% of the PhTX-III primary structure. The protein had its structure partially deduced by comparison with other proteins which data was already available in databases (NCBI and UniProt). Through such comparisons, it was possible to align the primary structure of PhTX-III with other similar PLA~2~, revealing great similarity with other toxins from different snake venoms ([Fig. 2](#f0010){ref-type="fig"}). The alignment was performed using Clustal Omega [@bib13], [@bib32], [@bib25].Fig. 2(A) Aligning and comparison of PhTX-III obtained peptides with other acidic PLA~2~ from snake venoms. All the molecules compared are acidic PLA~2~, isolated from snakes: *Bothrops diporus* (UniProt I2DAL4; UniProt I2DAL5), *Bothrops erythromelas* (UniProt Q2HZ28), *Trimeresurus gramineus* (UniProt P81479; P81480) *Bothrops pictus* (UniProt Q9I8F8). The asterisk (\*) means full consensus for that residue, colon (:) means partial consensus. The acidic residues are marked in red.

Some notable residues are present in the sequence: The calcium binding loop, comprehended between residues 25 and 33, Y--G--C--Y--C--G--X--G--G (being X a serine substitution in PhTX-III); the fragment C--C--F--V--H--D--C--C--Y--G--K, highly conserved in the PLA~2~, between residues 43 and 53, which contains part of the active site: H48, D49, Y52, D99.

The techniques applied revealed a protein with high identity with other already characterized PLA~2~ (up to 75% identity), all of them isolated from snake venoms, acidic and containing 122 aminoacids. That is a strong indication that PhTX-III is an acidic PLA~2,~ which was later confirmed by prediction of the isoelectric point, estimated as 5.04, using the software EMBOSS Pepstats [@bib13], [@bib25], [@bib28], [@bib32].

3.2. Enzymatic and biological activities {#s0080}
----------------------------------------

The PhTX-III presents phospholipolytic activity against the chromogenic substrate 4-nitro-3-(octanoyloxy) benzoic acid. The optimal temperature and pH are 37 °C ([Fig. 3](#f0015){ref-type="fig"}A) and 8.0 ([Fig. 3](#f0015){ref-type="fig"}B), respectively. The maximum velocity obtained by the substrate concentration studies was 10.81 U, with a Km of 4.43 mM. The enzyme is dependent of calcium ions to work properly and incubation with other divalent ions leads to loss of catalytic activity. Among the tested ions, magnesium-containing medium retained around 75% of the enzyme activity, and that is the best result. Zinc totally inhibits any trace of enzymatic activity ([Fig. 3](#f0015){ref-type="fig"}D).Fig. 3PhTX-III activities under different circumstances. (A and B) Effect of temperature and pH over enzyme activity, respectively. (C) Effect of substrate concentration over PhTX-III using chromogenic substrate 4-nitro-3-(octanoyloxy)benzoic acid. (D) Effects of different divalent ions over PhTX-III activity, with or without addition of Ca^+2^.

The maximum tested dose of 20 µg of the PhTX-III, do not exhibit myotoxicity or anticoagulant activity. The intramuscular and intravenous injections do not lead to increases in the plasma CK content, which would indicate muscular lesion. The protein is also unable to exert any antibacterial activity even at very high doses, up to 200 µg/ml.

As stated, the studied toxin does not show anticoagulant effect. In the PT test, the clothing time was 20.97±1.33 in the control group and 21.5±2.69 in PhTX-III presence. For the aPTT test, the coagulation times were 33.17±3.03 and 37.1±1.65 in control group and with toxin added, respectively. In both cases, there was no statistical difference.

PhTX-III exhibited intense inflammatory effect evaluated by cytokine analysis and moderate edema formation subsequent to footpad injection. The edematogenic effect was monitored in the course of 24 h and revealed a dose-dependent relationship in the edema size and persistency. The minimal edematogenic dose found was 5 μg, which caused a 30% increase in the paw size after one hour. In this same time, the 20 and 40 μg doses caused 39% and 51% in size increase, respectively ([Fig. 4](#f0020){ref-type="fig"}). The lower doses do not show any signs of edema after 24 h, but in the higher one, the edema persisted, with paw size increased by 27%.Fig. 4Edema-forming activity in mice pawn after PhTX-III injection. Results are shown in percentage of increase of the hind pawn after application of different concentrations of toxin, from 0.5 to 24 h. The determined minimal edematogenic dose was 5 µg.

Thirty minutes after the toxin injection, the levels of inflammatory cytokines IL-1α, IL-6 and TNF-α started to exhibit a different profile compared with the control mice, injected with PBS. TNF-α peaked one hour after toxin injection (reaching 2496.35±210.54 U/ml), but its concentration dropped quickly, standing close to basal levels after 3 h. IL-6 levels started to increase after 0.5 h, reaching its peak of 108.65±2.41 pg/ml at 3 h. After that, its concentration started to decrease reaching basal levels after 12 h. IL-1α concentration rose one hour after toxin injection, and kept its behavior until 6 h, where it reached a maximum concentration that was persistent until 12 h ([Fig. 5](#f0025){ref-type="fig"}). The cytokines concentration increase is another evidence of the inflammatory properties of PhTX-III.Fig. 5Plasmatic concentration of cytokines IL-1α (pg/ml), IL-6 (pg/ml) and TNF-α (U/ml) along 12 h after toxin injection. Empty markers represent measurements made in the control group and filled markers, the group that received PhTX-III.

The histological sections in the muscles injected with PBS buffer or PhTX-III confirmed that the toxin do not cause muscle damage, confirming by the CK analysis. The muscle integrity was clear in both cases. The difference observed is the great amount of inflammatory infiltrate present in the toxin-injected muscles, with large number of leukocytes. Dominici staining made possible the identification of these cells as mastocytes ([Fig. 6](#f0030){ref-type="fig"}).Fig. 6Sections of the gastrocnemius muscles from mice injected with PhTX-III or phosphate buffer, where: A, B, C -- HE stained muscle section, injected with phosphate buffer (A) and PhTX-III (B and C). D, E, F -- Dominici stained muscle section, injected with phosphate buffer (D) and PhTX-III (E, F). Bar in A, B: 40 μm. Bar in C, D, E, F: 20 μm.

4. Discussion {#s0085}
=============

In a constant effort to unveil the relationship between structure and function of the PLA~2~, our group isolated a novel acidic isoform from the venom of *Porthidium hyoprora*, with high catalytic activity but unable to exert myotoxic, anticoagulant or antibacterial activities.

After the PhTX-III isolation, the primary structure studies identified it as a group IIA PLA~2~ [@bib30]. The comparison of the partial primary structure with other PLA~2~ attested up to 75% of identity with acidic isoforms of that enzyme from different snake species venoms ([Fig. 2](#f0010){ref-type="fig"}). If observed properly in [Fig. 2](#f0010){ref-type="fig"}, the conserved residue sequences start and finish always one amino acid earlier than the usual by these enzymes. This happens due to a deletion of a residue, early in the chain, and it happens with frequency in the acidic group IIA PLA~2~, nevertheless the usual numbering is used in order to describe the conserved regions [@bib37], [@bib39], [@bib29]. This observation, along with the prediction of the isoelectric point, is another indication that the enzyme is acidic.

The phospholipolytic activity of PhTX-III was evaluated using the synthetic substrate 4-nitro-3-(octanoyloxy) benzoic acid and the values of optimal temperature and pH found were 37 °C and 8.0, respectively, which are very common and typical values for these enzymes [@bib36], [@bib2], [@bib10], [@bib16], [@bib17], [@bib27]. Comparing PhTX-III activity in a medium containing calcium, different divalent ions cannot support enzymatic activity properly. Other divalent ions seem to compete for the calcium binding site, and those with more similar ionic radii, like Zn^2+^ tend to cause more effective inhibition [@bib40].

It is usual to find snake venom acidic PLA~2~ with an only mild presence of pharmacological effects or totally missing them [@bib18], [@bib9], [@bib38]. PhTX-III lacks some pharmacological properties tested, usually presented by its basic counterparts. Even at high doses, PhTX-III is not able to exert myotoxic, anticoagulant or antimicrobial activities.

The region predicted to be responsible for the myotoxic effects of PLA~2~, comprehended between residues 79 and 87 contains negatively charged aminoacids and a very small amount of positive charges in PhTX-III. Kini and Evans [@bib20] affirmed based on observation of several myotoxic phospholipases A~2~, that this region must usually contain a great amount of positively charged residues in order to cause myotoxicity. Similarly, the enzyme site considered fundamental for the observation of antibacterial effects, must be rich in basic aminoacids. This area, the C-terminal region of the PLA~2~, contains several negatively charged residues, which is probably the responsible for its lack of antibacterial activity.

Even with absence of some classical pharmacological effects, PhTX-III exhibits intense inflammatory properties, with formation of edema and increase in plasma concentration of acute phase inflammatory cytokines ([Fig. 4](#f0020){ref-type="fig"}, [Fig. 5](#f0025){ref-type="fig"}). Edemas are caused by microvascular permeability increase and appear after 1 h of PhTX-III injection in the mice paw. The edemas can be induced by arachidonic acid, resulting from the phospholipase A~2~ catalysis, and by the release of IL-1 [@bib1], [@bib31].

Huancahuire-Vega et al. [@bib17] studying another PLA~2~ of the same venom, PhTX-I, verified its capacity of elevating IL-6 plasma concentration, with a peak of 95 pg/ml after 3 h after injection. PhTX-III causes a peak of the cytokine at the same time after injection, but with more pronounced IL-6 release, of 147 pg/ml. Other authors obtained similar results with different inflammatory capable PLA~2~ from different sources. In those, the cytokines serum concentrations peaked around three hours after toxin injection, same as in the present paper, but with less intensity [@bib23], [@bib2].

Research using a PLA~2~ isolated from *Bothrops roedingeri* revealed high inflammatory capabilities, with a similar behavior [@bib12]. As stated by the researcher, TNF-α, is likely to be induced by PLA~2~ action, which would induce the expression of selectins resulting in release of other interleukins, such as IL-1 and IL-6.

Histological observations in the toxin-injected tissues reveal no muscle damage, but great amount of inflammatory infiltrate, with large number of cells. Dominici staining made possible the identification of these as mast cells, as suspected by previous observations in sections stained with HE. Since there was no tissue damage or hemorrhage caused by PhTX-III, the source of cytokines can be explained by mast cell degranulation [@bib12], [@bib34].

Some phospholipases A~2~ can act on blood cells, including neutrophils [@bib24], macrophages [@bib41] and induction of mast cell degranulation [@bib3], [@bib21]. As mentioned in Section 1, many pharmacological effects caused by PLA~2~ requires catalytic activity or the presence of positive charges in its surface, in order to interact with the target, and mast cell degranulation is no exception to this rule [@bib26].

Based on the stated results, at least part of the inflammatory manifestations can be due to mast cell degranulation, caused by the action of PhTX-III. Although PhTX-III is an acidic enzyme, it still contains positively charged residues, in a lower proportion. Further studies of activities and structure comparison with other PLA~2~, basics and acids, can lead to future clues about what is the specific site of interaction between PLA~2~ and mast cells.
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